Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2020 Sep 3;15(9):e0238680. doi: 10.1371/journal.pone.0238680

Kidney function on admission predicts in-hospital mortality in COVID-19

Sinan Trabulus 1, Cebrail Karaca 1, Ilker Inanc Balkan 2, Mevlut Tamer Dincer 1, Ahmet Murt 1, Seyda Gul Ozcan 3, Rıdvan Karaali 2, Bilgul Mete 2, Alev Bakir 4, Mert Ahmet Kuskucu 5, Mehmet Riza Altiparmak 1, Fehmi Tabak 2, Nurhan Seyahi 1,*
Editor: Chiara Lazzeri6
PMCID: PMC7470363  PMID: 32881976

Abstract

Background

Recent data have suggested the presence of a reciprocal relationship between COVID-19 and kidney function. To date, most studies have focused on the effect of COVID-19 on kidney function, whereas data regarding kidney function on the COVID-19 prognosis is scarce. Therefore, in this study, we aimed to investigate the association between eGFR on admission and the mortality rate of COVID-19.

Methods

We recruited 336 adult consecutive patients (male: 57.1%, mean age: 55.0±16.0 years) that were hospitalized with the diagnosis of COVID-19 in a tertiary care university hospital. Data were collected from the electronic health records of the hospital. On admission, eGFR was calculated using the CKD-EPI formula. Acute kidney injury was defined according to the KDIGO criteria. Binary logistic regression and Cox regression analyses were used to assess the relationship between eGFR on admission and in-hospital mortality of COVID-19.

Results

Baseline eGFR was under 60 mL/min/1.73m2 in 61 patients (18.2%). Acute kidney injury occurred in 29.2% of the patients. In-hospital mortality rate was calculated as 12.8%. Age-adjusted and multivariate logistic regression analysis (p: 0.005, odds ratio: 0.974, CI: 0.956–0.992) showed that baseline eGFR was independently associated with mortality. Additionally, age-adjusted Cox regression analysis revealed a higher mortality rate in patients with an eGFR under 60 mL/min/1.73m2.

Conclusions

On admission eGFR seems to be a prognostic marker for mortality in patients with COVID-19. We recommend that eGFR be measured in all patients on admission and used as an additional tool for risk stratification. Close follow-up should be warranted in patients with a reduced eGFR.

Introduction

An outbreak of a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]; also termed as COVID-19) has emerged from Wuhan city, China in December 2019 and spread to over 214 countries and territories worldwide within six months [1]. The first case of COVID-19 in Turkey was confirmed on March 10, 2020, and the World Health Organization declared the disease a pandemic on March 11. In severe cases, acute respiratory failure due to diffuse alveolar damage constitutes the main clinical characteristics of COVID-19, whereas kidneys are among the most common extrapulmonary targets of the virus [1–3].

Chronic kidney disease (CKD) is associated with alterations of innate and adaptive immunity [4]. When compared to the general population, both the pneumonia risk and the mortality rate due to pneumonia are increased in patients with CKD [5, 6]. In line with this information, the European Renal Association—European Dialysis and Transplant Association (ERA-EDTA) suggested that CKD patients possess an increased risk for COVID-19 and related mortality [7]. It has also been recently shown that acute kidney injury (AKI) was related with mortality in coronavirus infections, including COVID-19 [8]. However, formal studies that examine on admission kidney function on COVID-19 mortality is largely missing.

In this study, we primarily aimed to investigate the effects of kidney function on the prognosis of COVID-19, exclusively focusing on the estimated glomerular filtration rate (eGFR) on admission, and secondarily to determine the rate of AKI in COVID-19 patients.

Materials and methods

The study protocol was approved by the Clinical Research Ethics Committee of Istanbul University Cerrahpasa (approval no: 2020–56318) and the Scientific Committee of the Ministry of Health (approval no: 2020-05-07T13_09_11). The study was conducted in accordance with the 1975 Declaration of Helsinki, as revised in 2013. The form of consent was not obtained because the data were analyzed anonymously. The ethics committee waived the requirement for informed consent.

Medical records of consecutive adult (>18 years) patients hospitalized between March 15 and May 1, 2020, were reviewed; outcomes data until June 1, 2020, were retrieved. The source of medical records was ISHOP (Istanbul University-Cerrahpasa Hospital Automation Program) electronic database system.

Setting

The study was conducted in a tertiary care university hospital in Istanbul, where approximately 60% of all cases in Turkey were reported [9]. Istanbul University—Cerrahpasa, Cerrahpasa Medical Faculty hospital is one of the largest university hospitals in Istanbul, with a total of 897 hospital beds, 270 of which were allocated for the current pandemic.

Patients

The diagnosis of COVID-19 was confirmed with at least one positive real-time reverse transcriptase-polymerase chain reaction (RT-PCR) test result in cases admitted with symptoms, signs and findings (laboratory / radiological) suggestive of COVID-19, according to the national guidelines [10].

Patients without any RT-PCR positivity, and those considered as ‘possible’ or ‘probable’ cases according to the Centers for Disease Control and Prevention (CDC) criteria were not included in the study (Fig 1) [11].

Fig 1. Flow chart showing the selection of the patients.

Fig 1

Open in a new tab

*Definitions are based on the European Centre for Disease Prevention and Control [11].

Diagnostic methodology

Combined pharyngeal and nasopharyngeal swab samples were obtained for the RT-PCR assay. In cases who were followed with invasive mechanical ventilation in the intensive care unit (ICU), lower respiratory tract specimens were also obtained.

RNAs were extracted using a commercial kit (BioSpeedy Nucleic Acid extraction kit; Bioeksen R & D Technologies Ltd., Istanbul, Turkey), followed by the detection of COVID-19 RNA using a commercial RT-PCR kit (Bio-Speedy COVID-19 RT-qPCR kit; Bioeksen R & D Technologies Ltd., Istanbul, Turkey) that targets the RdRP gene of COVID-19 in the samples. Both kits were used according to the manufacturer’s guidelines. The RT-PCR test was performed using 20 μl final volume using the following protocol: 5 min RT-PCR at 52°C, 10sec initial denaturation step at 95°C, followed by 40 cycles of 1 sec at 95°C, and 30 sec at 60°C. The Rotor-Gene Q 5plex HRM platform was used for amplification and detection.

Data collection and design

Demographic, clinical and laboratory data were retrieved from the electronic database of the hospital by two different teams from the Nephrology and Infectious Diseases departments, cross-checked, and then were screened for duplicate records, missing and erroneous data. The National Public Health Data Management System database was used as an external data source, particularly to track the molecular test results. Data regarding medications were obtained from the medical records of the patients and via the National Health Insurance database when necessary.

Clinical data consisted of symptoms and vital findings including temperature (on admission) and oxygen saturation (lowest levels). Comorbidities were retrieved from medical records. Patients using antihypertensive drugs were accepted as hypertensive, while those using antidiabetic drugs were accepted as diabetic. Laboratory data consisted of measurements of serum urea, creatinine, uric acid, sodium, potassium, calcium, albumin, lactate dehydrogenase (LDH), liver function tests (AST, ALT), C-reactive protein (CRP), procalcitonin, ferritin, D-dimer, fibrinogen, creatine phospho-kinase (CPK), hematocrit (Htc), white blood cell (WBC), lymphocyte, platelet count (PLT) and urinalysis on admission. Additionally, discharge and peak creatinine values were also collected. Two patients were found to have been admitted more than once; for laboratory data, first admission values were recorded, while mortality data were obtained from their last admission.

The data underlying this article can be shared upon a reasonable request to the corresponding author.

Study definitions

The date of hospital admission was accepted as the first day. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [12].

Acute kidney injury was defined as an acute increase in the serum creatinine level of at least 0.3 mg/dl within 48 hours or a 50% increase in the serum creatinine level within 7 days from the baseline, according to the KDIGO guideline. Staging of the AKI was also performed according to the same guideline [13]. Complete renal recovery was defined as the regression of the discharge creatinine level to the baseline creatinine level and partial renal recovery was defined as a difference of less than 0.3 mg/dl between the baseline and discharge creatinine levels.

Body temperature was measured using non-contact infrared thermometers, and the presence of fever was defined as a temperature of more than 37.8°C. Microscopic hematuria was accepted as the presence of ⩾1+ on dipstick urine testing or the presence of three or more erythrocytes per high-power field. Proteinuria was defined as the presence of ⩾1+ on dipstick urinalysis (at least 30–100 mg/dL).

Statistical analysis

Data were expressed as mean±standard deviation, if not stated otherwise. Categorical variables were compared using the chi-square test and two-tailed exact significances (Fisher’s exact test) were reported. Continuous variables were first analyzed for normality using the Kolmogorov-Smirnov test and then were compared using the paired samples t-test or the Mann-Whitney U test, when appropriate. Age-adjusted odds ratios were obtained with the use of logistic regression. Variables that were significantly associated with mortality in the age-adjusted analysis were used to construct a multivariate model. Binary logistic regression analysis with forward conditional selection was used to evaluate the determinants of in-hospital mortality. Age-adjusted survival was calculated using the Cox regression analysis.

All tests were performed using SPSS for Windows, version 22.0 software (SPSS Inc., Chicago, IL, USA). P values of less than 0.05 were considered statistically significant.

Results

Baseline demographic, clinical and laboratory parameters

We examined a total of 336 unique patients. The demographic and clinical characteristics of the patients, stratified by baseline eGFR are shown in Table 1. Patients were usually middle to old age (median: 54; range: 18 to 94 years) and male gender (57.1%) was more prominent. The most common symptoms at admission werecough in 156 (46.4%), fever in 119 (35.4%), dyspnea in 89 (26.5%), weakness in 58 (17.3%), diarrhea in 29 (8.6%), nausea/vomiting in 26 (7.7%), myalgia in 26 (7.7%), headache in 14 (4.2%), expectorating in nine (2.7%), and smell and taste disorder in two (0.6%) patients. On admission systolic blood pressure was slightly higher for the eGFR <60mL/min/1.73 m2 group, while there was no difference regarding on-admission diastolic blood pressure.

Table 1. Demographic and clinical characteristics of all patients and patients with a baseline eGFR <60 and ⩾60 mL/min/1.73 m2.

Characteristics All patients (n = 336) Patients with baseline eGFR <60 mL/min/1.73 m2 (n = 61) Patients with baseline eGFR ⩾60 mL/min/1.73 m2 (n = 275) p
Age (years) 55.0±16.0 69.9±12.9 51.7±14.7 <0.001
Gender, male 192 (57.1) 29 (47.5) 163 (59.3) 0.115
Diabetes mellitus 63 (18.8) 23 (37.7) 40 (14.5) <0.001
Hypertension 120 (35.7) 42 (68.9) 78 (28.4) <0.001
Systolic blood pressure (mmHg)1 122.4± 18.3 127.9±23.2 (n = 59) 121.0±16.6 (n = 234) 0.028
Diastolic blood pressure (mmHg)1 74.0± 10.8 75.3±11.5 (n = 59) 73.7±10.6 (n = 234) 0.254
Bronchial asthma 20 (6.0) 1 (1.6) 19 (6.9) 0.142
COPD 19 (5.7) 12 (19.7) 7 (2.5) <0.001
Heart failure 16 (4.8) 6 (9.8) 10 (3.6) 0.050
Malignancy 31 (10.1) 5 (9.8) 26 (10.2) 1.000
Open in a new tab

eGFR: estimated glomerular filtration rate, COPD: chronic obstructive pulmonary disease.

Data are expressed as mean±SD for quantitative parameters and n (%) for nominal parameters.

1Quantitative blood pressure data was available for 293 patients in the electronic health records. The remaining 43 were recorded as normal.

Hypertension was the most common comorbid disease, followed by diabetes mellitus (Table 1). Six patients were on chronic hemodialysis treatment, while only one patient had undergone kidney transplantation.

eGFR was <60 mL/min/1.73 m2 in minority of the patients (18.1%). These patients were older, and comorbid conditions such as diabetes, hypertension and chronic obstructive pulmonary disease (COPD) were more common among them (Table 1). On-admission laboratory data of the patients are shown in Table 2. Besides differences among the laboratory parameters that were related to our kidney function-based classification, patients with an eGFR <60mL/min/1.73 m2 had higher uric acid, potassium, LDH, ALT, CRP, procalcitonin, ferritin, D-dimer, WBC, and lower calcium, albumin, hematocrit levels, when compared to patients with an eGFR ≥60 mL/min/1.73 m2. The lowest oxygen saturation was taken into consideration in all patients. The oxygen saturation level in patients with an eGFR <60 mL/min/1.73 m2 was lower when compared to those with eGFR >60 mL/min/1.73 m2 (89.3±8.3% vs 92.4±5.9%, respectively; p:0.01). Urinalysis of the 67 patients confirmed that 23 patients had hematuria and 17 had proteinuria.

Table 2. Laboratory findings of all patients and patients with a baseline eGFR <60 and ⩾60 mL/min/1.73 m2.

Parameters All patients (n = 336) Patients with baseline eGFR <60 mL/min/1.73 m2 (n = 61) Patients with baseline eGFR ⩾60 mL/min/1.73 m2 (n = 275) p
Urea (mg/dL) 37.6±31.0 80.6±50.7 28.0±10.4 <0.001
Creatinine (mg/dL) 1.2±1.2 2.6±2.3 0.8±0.2 <0.001
Admission eGFR (mL/min/1.73 m2) 83.1±28.7 34.7±17.6 93.8±17.5 <0.001
Peak creatinine (mg/dL) 1.5±1.7 3.5±3.3 1.1±0.5 <0.001
Time to peak creatinine (day) 4.1±4.6 4.3±5.2 4.1±4.4 0.691
eGFR calculated using peak creatinine (mL/min/1.73 m2) 70.6±30.7 26.8±16.2 80.3±24.0 <0.001
Discharge creatinine1 (mg/dL) 1.1±1.1 2.4±2.2 0.9±0.4 <0.001
Discharge eGFR1 (mL/min/1.73 m2) 83.5±31.0 38.7±23.6 93.5±22.4 <0.001
Uric acid2 (mg/dL) 5.1±2.0 7.4±2.7 4.6±1.4 <0.001
Sodium (mEq/L) 137.7±3.8 137.0±4.9 137.8±3.6 0.229
Potassium (mEq/L) 4.3±0.5 4.5±0.8 4.3±0.5 0.029
Calcium1 (mg/dL) 8.7±0.6 8.5±0.6 8.8±0.6 <0.001
Albumin1 (g/dL) 3.9±0.5 3.5±0.5 4.0±0.5 <0.001
LDH (U/L) 298.6±287.4 361.8±280.1 284.6±287.6 0.016
AST (U/L) 38.6±73.7 67.3±163.6 32.2±23.5 0.614
ALT (U/L) 35.2±89.5 50.7±181.9 31.8±49.8 0.003
CRP (mg/dL) 57.9±72.6 97.5±88.1 49.1±65.7 <0.001
Procalcitonin3 (ng/mL) 1.4±9.3 2.7±8.8 1.1±9.4 <0.001
Ferritin4 (ng/mL) 506.8±889.6 892.0±1731.3 426.2±549.7 0.008
D-dimer (ng/mL) 1.6±3.1 3.2±4.3 1.2±2.6 <0.001
Fibrinogen5 (mg/dL) 443.8±165.1 458.6±160.3 440.5±166.3 0.467
CPK6 (U/L) 157.5±359.1 128.6±125.4 164.0±392.7 0.950
Hematocrit1 (%) 38.0±5.7 34.5±6.4 38.8±5.2 <0.001
White blood cell (/mm3) 6602.7±3491.1 7845.9±4414.9 6326.9±3195.7 <0.001
Lymphocyte (/mm3) 1519.0±1595.1 1226.2±706.6 1583.9±1725.7 0.113
Platelet (/mm3) 215087.1±150039.8 211426.2±115593.9 215899.1±156825.1 0.834
Open in a new tab

eGFR: estimated glomerular filtration rate, LDH: lactate dehydrogenase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, CRP: C-reactive protein, CPK: creatine phospho-kinase.

1There were missing data in less than three patients.

2Uric acid was measured in 325 patients.

3Procalcitonin was measured in 310 patients.

4Ferritin was measured in 318 patients.

5Fibrinogen was measured in 297 patients.

6CPK was measured in 301 patients.

Data are expressed as mean±SD.

Drugs used for the management of COVID-19 are summarized in Table 3. Favipiravir was more commonly used in patients with an eGFR <60 mL/min/1.73 m2. There were no statistically significant differences between the two groups (eGFR <60mL vs ≥60 mL/min/1.73 m2) regarding other drugs (Table 3).

Table 3. Drugs used in the treatments of all patients and patients with a baseline eGFR<60 and ⩾60 mL/min/1.73 m2.

Drug All patients (n = 336) Patients with baseline eGFR<60 mL/min/1.73 m2 (n = 61) Patients with baseline eGFR⩾60 mL/min/1.73 m2 (n = 275) p
Hydroxychloroquine 332 (98.8) 59 (96.7) 273 (99.3) 0.152
Oseltamivir 285 (84.8) 48 (78.7) 237 (86.2) 0.166
Azithromycin 294 (87.5) 51 (83.6) 243 88.4) 0.292
Favipiravir 169 (50.2) 41 (67.2) 128 (46.5) 0.004
Lopinavir/ritonavir 27 (8.0) 6 (9.8) 21 (7.6) 0.421
Tocilizumab 57 (17.8) 9 (14.8) 48 (17.5) 0.708
LWMH 192 (57.3) 40 (65.6) 152 (55.3) 0.115
Glucocorticoid 21 (6.3) 2 (3.3) 19 (6.9) 0.390
Open in a new tab

eGFR: estimated glomerular filtration rate, LMWH: low-molecular-weight heparin.

Data are expressed as n (%).

Prevalence of AKI, intensive care unit admission, and in-hospital mortality

Patients stayed in the hospital for 10 days on average. Acute kidney injury was detected in 98 patients (29.2%) and most (68.4%) of the AKI cases were Stage 1 (Table 4). Intensive care unit admission was necessary for 17.6% of the patients. During their hospitalization, 12.8% of the patients died.

Table 4. Incidence of acute kidney injury, intensive care unit admission and in-hospital mortality.

Characteristics All patients (n = 336) Patients with baseline eGFR <60 mL/min/1.73 m2 (n = 61) Patients with baseline eGFR ⩾60 mL/min/1.73 m2 (n = 275) p
Acute kidney injury 98 (29.2) 38 (62.3) 60 (21.8) <0.001
 Stage 1 67 (19.9) 29 (47.5) 38 (13.8) <0.001
 Stage 2 16 (4.8) 4 (6.6) 12 (4.4)
 Stage 3 15 (4.5) 5 (8.2) 10 (3.6)
Hospital stay (days) 10.2±7.0 11.9±6.8 9.8±7.1 0.007
ICU admission rate 59 (17.6) 21 (34.4) 38 (13.8) <0.001
In-hospital mortality 43 (12.8) 21 (34.4) 22 (8.0) <0.001
Open in a new tab

eGFR: estimated glomerular filtration rate, ICU: intensive care unit.

Data are expressed as mean±SD for quantitative parameters and n (%) for nominal parameters.

Patients with an eGFR <60 mL/min/1.73 m2 had longer hospital stays. Acute kidney injury was more common in patients with a baseline eGFR <60 mL/min/1.73 m2. All three stages of AKI were also more common in patients with a baseline eGFR <60 mL/min/1.73 m2 (Table 4). Continuous renal replacement therapy (RRT) was performed in four cases due to Stage 3 AKI, and in three of them, baseline eGFR was <60 mL/min/1.73 m2. Thirty-four patients with AKI have died (34.7%). We observed complete renal recovery in 36 (36.7%) and partial renal recovery in 23 patients (23.5%). Discharge creatinine remained 0.3 mg/dL above admission creatinine in five patients (5.1%). In-hospital mortality was significantly lower (3.7%, p<0.001) in patients without AKI compared to that of patients with AKI.

The ICU admission and in-hospital death rates were significantly higher in patients with a baseline eGFR <60 mL/min/1.73 m2 (Table 4). Specifically, three of the six patients who were on chronic hemodialysis treatment have also died, while one patient who had undergone kidney transplantation survived.

Determinants of in-hospital mortality

A total of 43 patients (12.8%) died during their hospital stay. Comparison of the demographic, clinical and laboratory findings of the deceased and living patients is given in Table 5. Patients who died were older and commonly had comorbid conditions such as diabetes, hypertension, COPD, heart failure and malignancy. Laboratory parameters associated with kidney function were worse in the patients who died. Compared to the patients who survived, deceased patients had higher uric acid, LDH, AST, CRP, procalcitonin, ferritin, D-dimer, CPK, WBC, and lower sodium, calcium, albumin, hematocrit, and lymphocyte levels (Table 5). On-admission systolic and diastolic blood pressures were not different between patients who died or survived. The association between old age and COVID-19 mortality is well known, therefore, we calculated the age-adjusted odds ratios of the study parameters for mortality (Table 5). According to the age-adjusted analysis, heart failure, malignancy, kidney function parameters, and sodium, calcium, albumin, LDH, AST, CRP, ferritin, D-dimer, Hct, WBC and lymphocyte levels were associated with mortality.

Table 5. Demographic, clinical and laboratory findings of patients who died and those who survived.

Parameters Patients who died (n = 43) Those who survived (n = 293) p Age adjusted OR CI 95% (min-max) p
Age 68.5±15.2 53.0±15.1 <0.001 NA NA NA
Gender, male 27 (62.8) 165 (56.3) 0.510 1.543 0.756–3.149 0.233
Diabetes mellitus 15 (34.9) 48 (16.4) 0.006 0.554 0.262–1.172 0.123
Hypertension 22 (51.2) 98 (33.4) 0.027 1.288 0.605–2.745 0.512
Systolic blood pressure (mmHg)1 127.5± 25.9 (n = 41) 121.6±16.7 (n = 252) 0.190 1.006 0.988–1.025 0.509
Diastolic blood pressure (mmHg)1 73.3± 12.6 (n = 41) 74.1± 10.5 (n = 252) 0.535 0.994 0.963–1.027 0.725
Bronchial asthma 1 (2.3) 19 (6.5) 0.489 3.087 0.382–24.965 0.290
COPD 6 (14.0) 13 (4.4) 0.023 0.613 0.206–1.822 0.379
Heart failure 8 (18.6) 8 (2.7) <0.001 0.234 0.076–0.717 0.011
Malignancy 17 (39.5) 14 (4.8) <0.001 0.046 0.017–0.121 <0.001
Urea (mg/dL) 71.4±58.3 32.6±20.5 <0.001 1.021 1.011–1.031 <0.001
Creatinine (mg/dL) 1.9±1.9 1.0±1.0 <0.001 1.367 1.109–1.685 0.003
Admission eGFR (mL/min/1.73m2) 59.7±37.4 86.5±25.6 <0.001 0.983 0.970–0.996 0.010
Peak creatinine (mg/dL) 3.3±2.6 1.2±1.4 <0.001 1.495 1.227–1.821 <0.001
Time to peak creatinine (day) 7.6±7.2 3.6±3.8 0.001 1.140 1.068–1.217 <0.001
eGFR calculated using peak creatinine (mL/min/1.73 m2) 30.6±27.2 76.4±26.5 <0.001 0.947 0.932–0.963 <0.001
Discharge creatinine (mg/dL) 2.2±1.5 0.9±0.9 <0.001 1.708. 1.280–2.280 <0.001
Discharge eGFR (mL/min/1.73 m2) 44.9±37.0 89.2±25.5 <0.001 0.960 0.948–0.973 <0.001
Uric acid (mg/dL) 6.0±3.1 5.0±1.8 0.045 1.109 0.953–1.291 0.182
Sodium (mEq/L) 135.5±5.6 138.0±3.4 0.006 0.861 0.792–0.936 <0.001
Potassium (mEq/L) 4.2±0.7 4.3±0.5 0.411 0.597 0.316–1.127 0.112
Calcium (mg/dL) 8.3±0.7 8.8±0.6 <0.001 0.429 0.253–0.728 0.002
Albumin (g/dL) 3.3±0.5 4.0±0.5 <0.001 0.075 0.032–0.175 <0.001
LDH (U/L) 439.2±687.8 263.6±130.1 <0.001 1.005 1.002–1.007 <0.001
AST (U/L) 71.8±100.6 33.7±67.7 <0.001 1.004 1.000–1.007 0.046
ALT (U/L) 66.8±215.4 30.5±48.4 0.863 1.005 0.999–1.011 0.102
CRP (mg/dL) 146.1±83.6 44.9±61.0 <0.001 1.012 1.008–1.017 <0.001
Procalcitonin (ng/mL) 3.1±9.3 1.1±9.3 <0.001 1.008 0.980–1.037 0.569
Ferritin (ng/mL) 1192.0±1910.1 419.3±608.7 <0.001 1.001 1.000–1.001 0.003
D-dimer (ng/mL) 5.0±6.6 1.1±1.7 <0.001 1.279 1.126–1.453 <0.001
Fibrinogen (mg/dL) 470.8±164.0 439.8±165.2 0.280 1.001 0.999–1.003 0.385
CPK (U/L) 182.1±162.4 153.7±381.1 0.033 1.001 1.000–1.001 0.192
Hematocrit (%) 32.3±6.3 38.9±5.1 <0.001 0.833 0.779–0.891 <0.001
White blood cell (/mm3) 8576.7±5553.0 6313.0±2981.5 0.005 1.000 1.000–1.000 0.009
Lymphocyte (/mm3) 883.7±532.7 1612.2±1676.3 0.005 0.998 0.997–0.999 <0.001
Platelet (/mm3) 176793.0±93824.5 220707.1±155927.0 0.073 1.000 1.000–1.000 0.054
Open in a new tab

NA: not applicable. COPD: chronic obstructive pulmonary disease, eGFR: estimated glomerular filtration rate, LDH: lactate dehydrogenase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, CRP: C-reactive protein, CPK: creatine phospho-kinase.

1Quantitative blood pressure data was available for 293 patients in the electronic health records. The remaining 43 were recorded as normal.

Data are expressed as mean±SD for quantitative parameters and n (%) for nominal parameters. Please refer to foot-note of Table 2 for specific number of measurements of each laboratory parameter.

We used Cox regression analysis to calculate the age-adjusted survival according to the eGFR group and prepared the survival curves accordingly (Fig 2). A baseline eGFR <60ml/min/1.73m2 was associated with a reduced survival rate (p: 0.021, OR: 2.161, CI 95%, min-max: 1.121–4.167).

Fig 2. Cumulative survival plots of the patients stratified by eGFR on admission.

Fig 2

Open in a new tab

The plots are prepared according to age-adjusted Cox regression analysis. The green line depicts patients with eGFR ⩾60 mL/min/1.73 m2 and the blue line depicts patients with eGFR <60 mL/min/1.73 m2.

Finally, we constructed a multivariate model to determine the in-hospital mortality rate using the variables that were available on admission and were significantly associated with mortality in the age-adjusted analysis. We did not include the data that were not available on admission (peak creatinine, discharge creatinine, associated eGFRs and time to peak creatinine) and associates of eGFR (urea and creatinine) in our prediction model. According to the multivariate model, malignancy, eGFR, CRP and Hct levels on admission were independent determinants of mortality (Table 6).

Table 6. Variables associated with mortality according to the multivariate binary logistic regression model.

Variables Age-adjusted OR CI 95% (min-max) p
Malignancy 29.412 7.194–125.000 <0.001
Admission eGFR (mL/min/1.73m2) 0.974 0.956–0.992 0.005
CRP (mg/dL) 1.012 1.005–1.018 <0.001
Hematocrit (%) 0.879 0.796–0.972 0.012
Open in a new tab

eGFR: estimated glomerular filtration rate, CRP: C-reactive protein.

Discussion

We showed that eGFR on admission was an independent determinant of mortality in patients with COVID-19. The association of COVID-19 with kidney function can be addressed in two reciprocal ways, which are not mutually exclusive; first, the effect of kidney disease on the course of COVID-19 can be examined, and second, the effect of COVID-19 on kidney function and development of AKI can be examined. In this paper, we mainly examined the first part of this association. Additionally, we also examined the rate of AKI. To the best of our knowledge, most studies have focused on the second part of this association from a clinical or histopathological point of view [2, 14–19].

In addition to pulmonary infiltration, SARS-CoV-2 may have cytopathic effects in many organs, including renal tissue [3]. It has been reported that ACE2, the cell entry receptor of SARS-CoV-2, is expressed almost 100 times higher in the kidneys than in the lungs [20, 21]. The pathogenesis of kidney disease in patients with COVID-19 is probably multifactorial, including direct cytopathic effects on kidney tissue, endothelial damage, deposition of immune complexes and virus-induced cytokines or mediators [1, 15, 22]. Su et al. investigated postmortem findings of COVID-19 patients and found evidence of the direct cytopathic effect of COVID-19 on kidney tissue. Moreover, endothelial damage was a common finding in renal histopathological analyses of 26 COVID-19 patients, in the absence of interstitial inflammatory infiltrates [3]. COVID-19 infection could cause endothelial dysfunction and a hypercoagulation state. This condition is aggravated by hypoxia, which augments thrombosis by both increasing blood viscosity and hypoxia-inducible transcription factor-dependent signaling pathway [23]. Hirsch et al. reported the incidence of AKI in a large cohort consisting of 5,449 patients and suggested ischemic acute tubular necrosis as an important aetiology for AKI in COVID-19 [19].

We report a high rate of AKI (29.2%) and a high mortality rate in patients with AKI (34.7%). According to previous clinical studies, the detection rate of AKI in patients with COVID-19 has been reported to vary between 0.5% and 36.6% [15, 17, 19]. Wang et al. claimed that COVID-19 was not associated with AKI [14]. Curiously, in that study, AKI was not reported even in the patients who died in the ICU. Cheng et al. reported AKI in 5.1% of a cohort of 701 patients [15]. The in-hospital death rate in their study was 16.1%, while it was calculated as high as 33.7% in those with elevated baseline serum creatinine levels. Another study from China examined 1,099 patients and found that mortality or ICU admission rates in patients with a higher creatinine level were higher (9.6%, n = 52) than those with normal creatinine levels (1%, n = 700) [17]. Chen at al. evaluated the characteristics of deceased COVID-19 patients and found that AKI was more frequent in patients who died (25%) when compared to those who survived (1%) [16]. In another study, Pei et al. reported that 6% of their patients experienced AKI [18], while Lim et al. found that the median age was higher in AKI patients [24]. Moreover, Lim et al. reported the highest rate of mortality in COVID-19 patients with AKI. The authors examined 164 hospitalized patients with COVID-19 and reported AKI in 18.3% of them, while in-hospital mortality was significiantly higher in patients with AKI (56.7%). Hirsch et al. reported the highest AKI rate (36.6%) among COVID-19 patients and the mortality rate of this group was 35% [19]. Continuous veno-venous hemodialysis (CVVHD) has been suggested as a safe method for treatment COVID-19 patients with AKI who need RRT [25].

Studies that analyzed the relationship between AKI or peak creatinine and the prognosis of COVID-19 might be prone to look-ahead bias. Therefore, we want to emphasize the importance of analyzing the relationship between kidney function on admission and mortality. We exclusively focused on baseline eGFR, since data on the peak creatinine level or development of AKI during the hospital stay are not available at the time of admission and risk stratification based on those characteristics might lead to a look-ahead bias. Similar to our findings, Cheng et al. recently showed that the prevalence of kidney disease during hospitalization in patients with COVID-19 was high and was associated with in-hospital mortality [15]. However, their analysis was based on creatinine levels; they did not use eGFR as a prognostic marker.

Heterogeneity of the results regarding the development of AKI might be explained by differences in baseline demographics, comorbid conditions and respiratory disease severity [19]. Moreover, there were differences among countries regarding their response to the pandemic. Besides the differences in the extent and types of social isolation measures, treatment algorithms, modalities and drug use were also different. Additionally, there are demographic differences between countries; all these factors might also affect clinical end-points. Therefore, having data from different countries and geographic regions is important to better understand and manage COVID-19 globally.

The following points summarize Turkey’s position regarding the baseline characteristics and its response to the pandemic. Turkey is one of the countries with a relatively young population (30.7% of the population is under the age of 20) and a wide health coverage through government programs [26, 27]. The number of hospital beds and ICUs per population is high [26]. Regarding COVID-19 treatment, early initiation of hydroxychloroquine was practiced, favipiravir use was widely adopted, and tocilizumab was used in all patients when indicated [10].

There are several limitations of our paper. First, urine analysis was not available in a large proportion of patients and we did not collect data on kidney imaging. Therefore, we might have overlooked some patients with CKD. Second, our follow-up duration was limited by the hospital stay period of the patients. The recovery patterns of kidney function might change during a longer follow-up. Third, we did not perform a formal power analysis to determine the sample size. However, we recruited all eligible patients that were hospitalized. Fourth, our study was performed in a leading university hospital; it is possible that we might have recruited more severe patients. Finally, the generalizability of our results to other countries might be limited since countries have adopted different treatment guidelines according to local regulations and the availability of health resources.

In conclusion, eGFR on admission seems to be a prognostic marker for mortality in patients with COVID-19. We recommend that eGFR be measured in all patients on admission and used as an additional tool for risk stratification. Close follow-up might be warranted in patients with a reduced eGFR.

Supporting information

S1 File. COVID-19 dataset.

File containing dataset used for the main analysis.

(XLSX)

Click here for additional data file. (190.4KB, xlsx)

Acknowledgments

We would like to thank secretary Gurbet Kaya for her valuable help during database editing.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. 10.1016/S0140-6736(20)30183-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Puelles VG, Lutgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and Renal Tropism of SARS-CoV-2. The New England journal of medicine. 2020;383(6):590–2. 10.1056/NEJMc2011400 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney international. 2020;98(1):219–27. 10.1016/j.kint.2020.04.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of immune dysfunction in end-stage renal disease. Clinical journal of the American Society of Nephrology: CJASN. 2008;3(5):1526–33. 10.2215/CJN.00950208 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Chou CY, Wang SM, Liang CC, Chang CT, Liu JH, Wang IK, et al. Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study. Medicine. 2014;93(27):e174 10.1097/MD.0000000000000174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. International urology and nephrology. 2020;52(6):1193–4. 10.1007/s11255-020-02451-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Association ERA-EDTA. COVID-19 News and Information. https://www.era-edta.org/en/covid-19-news-and-information/#toggle-id-16k. Published 2020. [Accessed: 12th June 2020].
  • 8.Chen YT, Shao SC, Lai EC, Hung MJ, Chen YC. Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and meta-analysis. Critical care. 2020;24(1):439 10.1186/s13054-020-03134-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Anadolu Agency. Turkey: Death toll from coronavirus rises to 277 Cases reported nationwide. https://www.aa.com.tr/en/health/turkey-death-toll-from-coronavirus-rises-to-277/1788522. Published 2020. [Accessed: 1st April 2020].
  • 10.Republic of Turkey Ministry of Health, Study of Scientific Board. https://hsgm.saglik.gov.tr/depo/birimler/goc_sagligi/covid19/rehber/COVID-19_Rehberi20200414_eng_v4_002_14.05.2020.pdf. Published 2020. [Accessed: 14th April 2020].
  • 11.European Centre for Disease Prevention and Control. Case definition for coronavirus disease 2019 (COVID-19). https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition. Published 2020. [Accessed: 29th May 2020].
  • 12.Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009;150(9):604–12. 10.7326/0003-4819-150-9-200905050-00006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Improving global outcomes (KDIGO) acute kidney injury work group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138. [Google Scholar]
  • 14.Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. American journal of nephrology. 2020;51(5):343–8. 10.1159/000507471 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney international. 2020;97(5):829–38. 10.1016/j.kint.2020.03.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Bmj. 2020;368:m1091 10.1136/bmj.m1091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine. 2020;382(18):1708–20. 10.1056/NEJMoa2002032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. Journal of the American Society of Nephrology: JASN. 2020;31(6):1157–65. 10.1681/ASN.2020030276 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney international. 2020;98(1):209–18. 10.1016/j.kint.2020.05.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. 10.1038/s41586-020-2012-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on Kidney Dysfunctions of COVID-19 Patients. medRxiv. 2020:2020.02.08.20021212. 10.1101/2020.02.08.20021212 [DOI] [Google Scholar]
  • 22.Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. Journal of clinical medicine. 2020;9(5). 10.3390/jcm9051417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thrombosis research. 2019;181:77–83. 10.1016/j.thromres.2019.07.013 [DOI] [PubMed] [Google Scholar]
  • 24.Lim JH, Park SH, Jeon Y, Cho JH, Jung HY, Choi JY, et al. Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury. Journal of clinical medicine. 2020;9(6). 10.3390/jcm9061718 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Nalesso F, Garzotto F, Cattarin L, Gobbi L, Qassim L, Sgarabotto L, et al. A Continuous Renal Replacement Therapy Protocol for Patients with Acute Kidney Injury in Intensive Care Unit with COVID-19. Journal of clinical medicine. 2020;9(5). 10.3390/jcm9051529 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Turkish statistical institude. https://biruni.tuik.gov.tr/medas/?kn=95&locale=tr. Published 2020. [Accessed: 14th June 2020].
  • 27.Ministry of Health of Turkey. Turkey Health Statistics Yearbook 2018. https://dosyasb.saglik.gov.tr/Eklenti/36164,siy2018en2pdf.pdf?0. Published 2018. [Accessed: 14th June 2020].

Decision Letter 0

Chiara Lazzeri

31 Jul 2020

PONE-D-20-18434

Kidney function on admission predicts in-hospital mortality in COVID-19

PLOS ONE

Dear Dr. Seyahi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The introduction section is not easy to read. Available evidence should be more clearly summarized and the rationale should be more clearly stated. The manuscript needs an extensive English revision. 

Please submit your revised manuscript by Sep 14 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Chiara Lazzeri

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for including your ethics statement: 'The study protocol was approved by the local medical ethical committee (approval no: 2020-56318) and the Scientific Committee of the Ministry of Health (approval no: 2020-05-07T13_09_11).'

(a) Please amend your current ethics statement to include the full name of the ethics committee that approved your specific study. 

(b) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them; b) the date range (month and year) during which patients' medical records were accessed; and c) the source of the medical records analyzed in this work (e.g. hospital, institution or medical center name). If the ethics committee waived the requirement for informed consent, please include this information.

4. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.  

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

  • The name of the colleague or the details of the professional service that edited your manuscript

  • A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

  • A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

5. Thank you for stating the following financial disclosure:

"NO"

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. Thank you for stating the following in your Competing Interests section: 

"NO"

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

 This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

7. Please upload a copy of Figures 1, 2, to which you refer in your text on pages 7 and 23. If the figures are no longer to be included as part of the submission please remove all reference to them within the text.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Although this reviewer warmly welcomes this manuscript, some issues should be addressed:

-The rationale for the study is unclear as the introduction is a bit confusing, comprising several pieces of apparently unlinked information. A more integrated appraisal of the relevant literature would be appropriate to provide the context for the study.

-Figures were not available.

-The following reports should be mentioned:

J Clin Med. 2020 Jun 3;9(6):E1718; doi: 10.3390/jcm9061718; PMID: 32503180.

J Clin Med. 2020;9(5):1529. doi: 10.3390/jcm9051529. PMID: 32438617.

-Values of systolic and diastolic blood pressure should be included in the analysis.

-The key role of endothelial dysfunction in the pathophysiology of kidney injury in COVID-19 (J Clin Med. 2020 May 11;9(5):1417; doi: 10.3390/jcm9051417; PMID: 32403217) should be better discussed.

-English language (syntax, grammar, correct choice of words, correct use of adjectives and adverbs) should be substantially improved throughout the text. Professional assistance should be sought.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Sep 3;15(9):e0238680. doi: 10.1371/journal.pone.0238680.r002

Author response to Decision Letter 0

17 Aug 2020

(This has also been sent as a separate file)

Editorial Review Board Comments:

1- Thank you for including your ethics statement: 'The study protocol was approved by the local medical ethical committee (approval no: 2020-56318) and the Scientific Committee of the Ministry of Health (approval no: 2020-05-07T13_09_11).'

(a) Please amend your current ethics statement to include the full name of the ethics committee that approved your specific study.

(b) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

Response: We made the suggested changes.

2. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them; b) the date range (month and year) during which patients' medical records were accessed; and c) the source of the medical records analyzed in this work (e.g. hospital, institution or medical center name). If the ethics committee waived the requirement for informed consent, please include this information.

Response: a) We anonymized the database during our analysis. b) We accessed the database between March 15 and May 1, 2020. c) The source of medical records was ISHOP (Istanbul University-Cerrahpasa Hospital Automation Program) electronic database system. d) The ethics committee waived the requirement for informed consent.

3. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services. If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

• The name of the colleague or the details of the professional service that edited your manuscript

• A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

• A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

Response: The manuscript was edited by Edvard Tony Karakas from Daria Consulting, Turkey.

Response to Reviewer

Reviewer #1: Although this reviewer warmly welcomes this manuscript, some issues should be addressed:

1. The rationale for the study is unclear as the introduction is a bit confusing, comprising several pieces of apparently unlinked information. A more integrated appraisal of the relevant literature would be appropriate to provide the context for the study.

Response: We are sorry for this inconvenience. Apparently, a part of the introduction was deleted inadvertently during the submission. Following your comment, we became aware of this error and corrected the relevant section.

2. Figures were not available.

Response: We are sorry for this inconvenience. We believe that the figures were deleted because of a technical issue during the submission. We checked that they are correctly incorporated to the revised manuscript.

3. The following reports should be mentioned:

J Clin Med. 2020 Jun 3;9(6):E1718; doi: 10.3390/jcm9061718; PMID: 32503180.

J Clin Med. 2020;9(5):1529. doi: 10.3390/jcm9051529. PMID: 32438617.

Response: Thank you for providing us those important studies. We cited them in the revised manuscript.

4. Values of systolic and diastolic blood pressure should be included in the analysis.

Response: We collected the systolic and diastolic blood pressure records from our hospital electronic database and we made the necessary analysis in the revised manuscript.

5. The key role of endothelial dysfunction in the pathophysiology of kidney injury in COVID-19 (J Clin Med. 2020 May 11;9(5):1417; doi: 10.3390/jcm9051417; PMID: 32403217) should be better discussed.

Response: Thank you for providing us this important paper. We extended the Discussion section with the help of this paper.

6. English language (syntax, grammar, correct choice of words, correct use of adjectives and adverbs) should be substantially improved throughout the text. Professional assistance should be sought.

Response: With the assistance of a professional service, we revised the manuscript regarding language issues.

Attachment

Submitted filename: Response to Reviews.docx

Click here for additional data file. (21KB, docx)

Decision Letter 1

Chiara Lazzeri

24 Aug 2020

Kidney function on admission predicts in-hospital mortality in COVID-19

PONE-D-20-18434R1

Dear Dr. Seyahi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Chiara Lazzeri

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Chiara Lazzeri

27 Aug 2020

PONE-D-20-18434R1

Kidney function on admission predicts in-hospital mortality in COVID-19

Dear Dr. Seyahi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Chiara Lazzeri

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. COVID-19 dataset.

    File containing dataset used for the main analysis.

    (XLSX)

    Click here for additional data file. (190.4KB, xlsx)
    Attachment

    Submitted filename: Response to Reviews.docx

    Click here for additional data file. (21KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.

    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES